Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020

J Gen Intern Med. 2022 Jan;37(1):176-178. doi: 10.1007/s11606-021-07175-9. Epub 2021 Oct 26.

Authors

Zachary Levin¹, Jessica Chang¹, Pinar Karaca-Mandic², Alí Duarte-García³, Molly Moore Jeffery^{4

5}

Affiliations

¹ University of Minnesota School of Public Health, Minneapolis, MN, USA.
² Carlson School of Management, University of Minnesota, Minneapolis, MN, USA.
³ Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Health Care Delivery Research and Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. jeffery.molly@mayo.edu.
⁵ OptumLabs Visiting Fellow, Eden Prairie, MN, USA. jeffery.molly@mayo.edu.

No abstract available

Publication types

Letter
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Humans
Hydroxychloroquine*
United States / epidemiology

Substances

Hydroxychloroquine

Grants and funding

R01 HS025164/HS/AHRQ HHS/United States